clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Hoshi T et al. | Cell damage and proliferation in human gastric mucosa infected by Helicobacter pylori--a comparison before and after H pylori eradication in non-atrophic gastritis. | 1999 | Hum. Pathol. | pmid:10667417 |
Mordi MN et al. | Acid-catalyzed degradation of clarithromycin and erythromycin B: a comparative study using NMR spectroscopy. | 2000 | J. Med. Chem. | pmid:10669574 |
Griffith DE et al. | Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. | 2000 | Clin. Infect. Dis. | pmid:10671330 |
Miyabayashi H et al. | Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori. | 2000 | Helicobacter | pmid:10672049 |
Dammann HG et al. | Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. | 2000 | Helicobacter | pmid:10672051 |
Calvet X et al. | Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study. | 2000 | Helicobacter | pmid:10672052 |
Sevin E et al. | [Helicobacter pylori: identification and detection of clarithromycin resistance by gene amplification]. | 2000 Jan-Feb | Ann. Biol. Clin. (Paris) | pmid:10673617 |
Kohri K et al. | Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. | 2000 | Eur. Respir. J. | pmid:10678622 |
Jung R et al. | Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes. | 2000 | Antimicrob. Agents Chemother. | pmid:10681358 |
Suleymanlar I et al. | Response to triple treatment with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori infections in continuous ambulatory peritoneal dialysis patients. | 1999 | Adv Perit Dial | pmid:10682076 |
Sugimoto M et al. | Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication. | 2000 | Am. J. Gastroenterol. | pmid:10685780 |
Gotfried MH | Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance. | 2000 | Clin Ther | pmid:10688386 |
Bayerdörffer E | [The MACH2 Study: value of inhibiting gastric acid secretion in eradication of Helicobacter pylori with a one week triple therapy protocol]. | 2000 | Z Gastroenterol | pmid:10689750 |
Szlachcic A et al. | Helicobacter pylori and its eradication in rosacea. | 1999 | J. Physiol. Pharmacol. | pmid:10695558 |
Georgopoulos SD et al. | Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. | 2000 | Dig. Dis. Sci. | pmid:10695615 |
Dore MP et al. | Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. | 2000 | Dig. Dis. Sci. | pmid:10695616 |
Miwa H et al. | Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. | 2000 | Dig. Dis. Sci. | pmid:10695617 |
Shamaly H et al. | Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis. | 2000 | J. Pediatr. Gastroenterol. Nutr. | pmid:10697140 |
Ives TJ et al. | In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected vero cell monolayers. | 2000 | J. Antimicrob. Chemother. | pmid:10702548 |
Schweeger I et al. | Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers. | 2000 | Thromb. Res. | pmid:10704650 |